Quick Answer
Contineum Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2024.
- Contineum Therapeutics, Inc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2023 to 2024.
- This data is from Contineum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2025.
- XBRL data for this metric is available from 2023 to 2024 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $50.00 million | Q3 2023: $0.00 | Q2 2024: $0.00 | Q3 2024: $0.00.
- Historical annual values: Fiscal year 2024: $0.00 | Fiscal year 2023: $50.00 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: